Skip to main content

Table 4 Patients characteristics in the conversion group

From: Clinical efficacy of liver resection after downsizing systemic chemotherapy for initially unresectable liver metastases

  Age (years) Sex Primary T category Node positive Tumor size (mm) Tumor number Regimen No. of lines No. of cycles Clinical response Resection
1 65 M Colon 3 + 80 ≥5 Cmab + FOLFIRI 1 3 PR 1
2 57 M Rectum 3 + 50 ≥5 Bmab + FOLFOX6 1 17 PR 0
3 52 F Colon 4 + 30 ≥5 Cmab + FOLFIRI 1 3 PR 1
4 51 M Colon 3 20 2–4 Bmab + FOLFOX6 1 18 PR 0
5 60 M Rectum 4 + 50 ≥5 Cmab + FOLFOX6 1 7 PR 1
6 67 M Colon 4 30 ≥5 Cmab + FOLFOX6 1 8 PR 1
7 78 M Colon 3 20 ≥5 Cmab + FOLFOX6 1 15 PR 1
8 32 F Colon 3 + 100 ≥5 Bmab + FOLFOX6 1 8 SD 1
9 80 F Colon 3 32 ≥5 Bmab + FOLFOX6 1 4 PR 0
10 44 F Colon 3 + 100 ≥5 Cmab + FOLFOX6 1 3 SD 0
11 33 F Colon 3 + 24 ≥5 Bmab + FOLFOX6 1 2 PR 0
12 56 F Colon 3 80 2–4 Cmab + FOLFOX6 1 3 PR 0
13 58 M Colon 3 + 40 ≥5 Cmab + FOLFIRI/Bmab + Xelox 2 18 PR 1
14 55 F Colon 4 55 ≥5 Cmab + FOLFOX6 1 3 PR 0
15 58 F Rectum 3 + 40 1 Cmab + FOLFOX6 1 3 SD 0
16 65 M Rectum 3 23 ≥5 Pmab + FOLFOX6 1 3 PR 0
  1. M male, F female, Cmab cetuximab, Bmab bevacizumab, PR partial response, SD stable disease